A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

Type of Cancer
Solid Tumor

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.